Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Petros Pharmaceuticals Inc (NQ: PTPI ) 0.3450 +0.0002 (+0.06%) Streaming Delayed Price Updated: 3:58 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Petros Pharmaceuticals Inc < Previous 1 2 Next > Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil) July 29, 2024 Via ACCESSWIRE Petros Pharmaceuticals’ STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance July 16, 2024 Via ACCESSWIRE Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch May 29, 2024 Via ACCESSWIRE Petros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRA May 21, 2024 Via ACCESSWIRE Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals May 14, 2024 Lemonaid Health will offer customers more affordable access to fast-acting branded ED medication that works as quickly as 15 minutes prior to sexual activity From 23andMe, Inc. Via GlobeNewswire Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil) April 16, 2024 Via ACCESSWIRE Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider February 14, 2024 Via ACCESSWIRE Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe May 14, 2024 Via ACCESSWIRE Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health April 23, 2024 Via ACCESSWIRE Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status April 02, 2024 Via ACCESSWIRE Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider March 19, 2024 Via ACCESSWIRE BestGrowthStocks.Com Issues Comprehensive Analysis of Petros Pharmaceuticals Inc March 11, 2024 NEW YORK, NY / NewsDirect / March 11th, 2024 / Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing... Via TheNewswire.com Exposures Product Safety Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC Switch January 24, 2024 Via ACCESSWIRE Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor’s (rosuvastatin) OTC Switch Technology Provider December 12, 2023 Via ACCESSWIRE Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's (rosuvastatin) OTC Switch Technology Provider December 05, 2023 Via ACCESSWIRE Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC Switch January 17, 2024 Via ACCESSWIRE Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status December 12, 2023 Via ACCESSWIRE Petros Pharmaceuticals Petros Pharmaceuticals Developing Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R) October 30, 2023 Via ACCESSWIRE Following Encouraging FDA Feedback Petros Pharmaceuticals Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA October 19, 2023 Via ACCESSWIRE Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential OTC STENDRA Label October 04, 2023 Via ACCESSWIRE Petros Pharmaceuticals to Present at the LD Micro Main Event XVI September 28, 2023 Via ACCESSWIRE Petros Pharmaceuticals Provides Letter to Shareholders September 11, 2023 Via ACCESSWIRE Petros Pharmaceuticals Announces Capital Raise of $15 Million July 13, 2023 Via ACCESSWIRE Petros Pharmaceuticals Announces Reverse Stock Split November 30, 2022 Via ACCESSWIRE Petros Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 06, 2023 Via ACCESSWIRE Petros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Update November 15, 2022 Via ACCESSWIRE New FDA-Approved Labeling for Petros Pharmaceuticals’ STENDRA (avanafil) Now Includes Efficacy Data Regarding Use in Men Who Have Undergone Radical Prostatectomy October 25, 2022 Via ACCESSWIRE Petros Pharmaceuticals to Participate in Two October 2022 Conferences October 21, 2022 Via ACCESSWIRE Internationally Published, Head-to-Head Data From India of Petros Pharmaceuticals' STENDRA(R) (Avanafil) Tablets Reported Improvement in Erectile Function Compared to Sildenafil and Baseline After 12 Weeks of Therapy September 08, 2022 Via ACCESSWIRE Petros Pharmaceuticals Reports Record Revenue and Gross Profit During Second Quarter 2022 August 15, 2022 Via ACCESSWIRE < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.